Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by Analysts

Key Points

• Sarepta Therapeutics has received a consensus rating of "Hold" from 29 analysts, with 6 sell ratings, 15 hold ratings, and 8 buy ratings.
• The average 12-month price target for Sarepta Therapeutics is $43.50, despite recent stock performance showing considerable volatility.
• In their latest earnings report, Sarepta posted an EPS of $2.02, exceeding expectations and reflecting a 68.4% increase in quarterly revenue year-over-year.

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been given a consensus rating of "Hold" by the twenty-nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $43.50.

A number of equities analysts have recently commented on the company. Baird R W cut Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. Morgan Stanley boosted their price objective on Sarepta Therapeutics from $15.00 to $20.00 and gave the company an "equal weight" rating in a report on Tuesday, July 29th. Bank of America boosted their price objective on Sarepta Therapeutics to $17.00 and gave the company an "underperform" rating in a report on Wednesday, August 20th. Piper Sandler boosted their price objective on Sarepta Therapeutics to $15.00 and gave the company a "neutral" rating in a report on Tuesday, July 29th. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of Sarepta Therapeutics in a report on Monday, June 16th.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $18.71 on Monday. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -21.51 and a beta of 0.49. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The stock has a 50 day moving average price of $17.78 and a 200-day moving average price of $43.48. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million during the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The company's quarterly revenue was up 68.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.07 EPS. Equities analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of large investors have recently bought and sold shares of SRPT. Federated Hermes Inc. boosted its holdings in Sarepta Therapeutics by 347.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company's stock valued at $22,370,000 after acquiring an additional 1,016,069 shares during the period. Norges Bank bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at $15,619,000. Y Intercept Hong Kong Ltd raised its position in Sarepta Therapeutics by 1,736.5% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company's stock valued at $14,880,000 after purchasing an additional 822,799 shares in the last quarter. Aberdeen Group plc raised its position in Sarepta Therapeutics by 91.1% during the 2nd quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company's stock valued at $21,500,000 after purchasing an additional 592,125 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its position in Sarepta Therapeutics by 438.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock valued at $45,477,000 after purchasing an additional 580,123 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.